Michael Stephen Porrazzo, MD

Juan Pretell, M.D., is a musculoskeletal oncology surgeon and the chief of musculoskeletal oncology surgery at Miami Cancer Institute. Dr. Pretell specializes in benign and malignant musculoskeletal tumors and skin cancers affecting the musculoskeletal system. He is fluent in English and Spanish.Prior to joining Miami Cancer Institute in 2022, Dr. Pretell worked at University of Miami where he was an Associate Professor of Orthopedic and Faculty of the Orthopedic Surgery residency program and Musculoskeletal Oncology Fellowship. He also was the director of clinical research in the Division of Musculoskeletal Oncology Surgery.Dr. Pretell’s research has been published in high-impact national and international orthopedic and oncology journals. He has been a speaker in national and international meetings, and faculty for international Musculoskeletal Oncology courses. He is an active member of the Musculoskeletal Tumor Society and fellow of the AAOS. He is also a Diplomate of the American Board of Orthopedic Surgeons.Dr. Pretell’s approach to patient care is to view patients and their families as his own family members. He is honest and open about the diagnosis and the treatment options available with the most current, evidence-based medicine. When he is not treating patients, Dr. Pretell enjoys going to arcades, cooking classes and entertainment activities with his oldest stepson and his triplets, watching movies with his oldest daughter, traveling and taking beach walks with his wife. He is also an avid World Cup soccer fan.

Ryan Matthew Kahn, M.D., MHS, FACOG, is a gynecologic oncologist at Baptist Health Miami Cancer Institute. He specializes in minimally invasive surgical techniques, particularly robotic-assisted surgery. When appropriate, this approach offers patients faster recovery, less postoperative pain, shorter hospital stays and improved cosmetic outcomes. Dr. Kahn incorporates clinical genetics in his practice to improve care and prevention strategies for patients and families carrying BRCA and other hereditary breast and ovarian cancer gene variants. He also specializes in ovarian cancer cytoreductive surgery, which aims to remove all visible disease during ovarian cancer surgery. This approach has been consistently linked to improved patient survival. After earning a bachelor’s degree from Johns Hopkins University and a master’s degree in biochemistry and molecular biology at Johns Hopkins Bloomberg School of Public Health in Baltimore, Dr. Kahn earned his medical degree with research distinction at the University of Miami Miller School of Medicine. He completed a four-year obstetrics and gynecology residency at New York Presbyterian Hospital – Weill Cornell Medicine in New York City. He remained in New York for four more years to complete a gynecologic oncology fellowship at the prestigious Memorial Sloan Kettering Cancer Center. During his fellowship, Dr. Kahn was actively involved in research focused on innovative immunotherapies for ovarian cancer. His positive research results, which included delayed tumor growth and a transformed tumor microenvironment, offer a promising rationale for clinical trials in patients with advanced ovarian cancer. He also conducted research on the regionalization of care for gynecologic malignancies, which involves directing complex surgical procedures to specialized, high-volume centers and surgeons to improve patient outcomes by leveraging the expertise and experience of these centers. Dr. Kahn has published his research work in medical journals and textbooks presented his findings at national symposiums. Dr. Kahn is committed to providing the highest level of surgical and medical care, rooted in compassion, excellence and respect for each patient’s background, values and goals. He believes in shared decision-making, collaborating with his patients to ensure they are informed, involved and empowered to choose a treatment plan that best suits their individual values and preferences. He promises to bring every ounce of skill and effort to help his patients achieve the best possible outcome – not just as their surgeon, but as their partner in care. As a proud South Florida native, Dr. Kahn is a passionate supporter of the local professional sports teams as well as the University of Miami Hurricanes. He enjoys spending time with his family and friends, going to the beach to recharge and running long-distance races. He participated in the New York City Marathon every year during his four-year fellowship and plans to run the Miami Marathon and participate in Bounce Back from Cancer in support of gynecologic cancer programs at Miami Cancer Institute.

Murugesan Manoharan, M.D., FRACS, is a surgical urologic oncologist and the chief of urologic oncology surgery at Miami Cancer Institute. Dr. Manoharan specializes in the treatment of genitourinary cancers, including bladder, kidney, prostate and testicular cancer. Dr. Manoharan also serves as the chairman of the Department of Urology at Baptist Health South Florida and a professor of urology at Herbert Wertheim College of Medicine, Florida International University.In 2022, the Abbhi Family Endowed Chair in Urologic Oncology was created to help Dr. Manoharan and the Institute conduct research and clinical trials to improve survival rates and quality of life for patients with bladder cancer.He joined Miami Cancer Institute from the Sylvester Comprehensive Cancer Center, where he served as one of the site disease group leaders for genitourinary cancers. He also practiced urology at Jackson Memorial Hospital and the Veterans Affairs Medical Center in Miami.Dr. Manoharan is a renowned leader in the treatment of prostate cancer, kidney cancer, bladder cancer and other urologic malignancies. He is an expert in minimally invasive surgery, including nerve sparing robotic prostatectomy, robotic kidney surgery, robotic bladder removal and neobladder reconstruction. Dr. Manoharan was one of the first urologists in the United States to perform robotic bladder removal surgery and reconstruction of neobladder using a Pfannenstiel incision. He also specializes in other minimally invasive ablative cancer procedures, such as high-intensity focused ultrasound (HIFU) therapy, cryotherapy and the NanoKnife procedure to treat prostate cancer. He has extensive experience training medical students, residents and oncology fellows. He has won numerous awards for his teaching and clinical excellence, as well as his research work. Dr. Manoharan’s research interests include stem cell applications, biomarkers and cancer outcomes. He serves as an editorial reviewer for several scientific publications. He is also widely published in peer-reviewed medical journals and is an invited speaker at national and international scientific symposiums. Dr. Manoharan has authored more than 140 scientific articles and 15 textbook chapters and has presented papers and posters at more than 100 national and international meetings. He served as vice chairman and a member of the International Bladder Cancer Guidelines committee, organized by the WHO and Société Internationale d'Urologie.When he is not treating patients, Dr. Manoharan enjoys music and traveling.